Geron Corporation (GERN) SEC Filings & Earnings Calls

Dependence on single product RYTELO for revenue; pipeline risk.

“All revenue from RYTELO; Phase 3 IMpactMF trial ongoing.”

Non-cash inventory costs impacting reported margins.

“Cost of goods sold increased to $9.2M from $1.2M due to non-cash inventory expenses.”

Securities litigation risk

“We and certain of our current and former officers and directors have been named as defendants in securities class action lawsuits and derivative lawsuits.” · word for word

Commercial execution risk

“our strategy to drive sales growth and our ongoing commercialization efforts have not to date achieved and may not in the future achieve meaningful sales growth” · word for word

Tariff risk

“the active pharmaceutical ingredient, or API, for imetelstat is manufactured in South Korea and our 47mg vial of RYTELO drug product is currently manufactured in Italy.” · word for word

Nasdaq delisting risk

“our stock has traded as low as $1.07 per share through July 31, 2026”

Securities class action and derivative lawsuits

“On March 13 and March 14, 2025, we and certain of our current and former officers were named as defendants in two putative securities class action lawsuits” · word for word

Tariff exposure on international supply chain

“the active pharmaceutical ingredient, or API, for imetelstat is manufactured in South Korea and our 47mg vial of RYTELO drug product is currently manufactured in Italy.” · word for word

Commercial execution risk for RYTELO

“our strategy to drive sales growth and our ongoing commercialization efforts has not to date achieved and may not in the future achieve meaningful sales growth” · word for word

Stock price volatility and potential Nasdaq delisting

“Between April 1, 2025 and March 31, 2026, the price has ranged between a high of $1.95 per share and a low of $1.04 per share.” · word for word

Dependence on single product RYTELO

“our ability to generate meaningful revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO in the U.S. for lower-risk MDS or to expand its indications of use.” · word for word

Commercial execution risk for RYTELO

“Achieve U.S. annual net revenue for RYTELO of: 1) $200 million (20% weighted payout) ... Achieved U.S. annual net revenue for RYTELO of $183.6 million Partially achieved 15%” · word for word

Leadership transition risk

“On March 10, 2025, Dr. Scarlett, our former President and Chief Executive Officer and Chairman of the Board, ceased serving as our President and Chief Executive Officer and resigned as a member of the Board.” · word for word

Restructuring execution risk

“The restructuring plan resulted in a reduction in headcount of approximately one-third of our workforce.” · word for word

No material risk; standard director appointments.

“No related-party transactions or unusual arrangements.”

“If we do not generate net revenues from commercial sales of RYTELO at the levels we anticipate, if we experience unforeseen events or choose to make other investments in our business, or our assumptions regarding our projected operating expenses are otherwise incorrect, we may require additional funding.” · word for word

“Based on our current assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.” · word for word

“If we do not generate sufficient funds from commercial sales of RYTELO, if we experience unforeseen events or choose to make other investments in our business, or our assumptions regarding our projected operating expenses are otherwise incorrect, we may require additional funding to fund our material cash requirements.” · word for word

RYTELO revenue growth is modest (1% QoQ) and the company remains unprofitable with net losses. Cash burn continues.

“Net loss of $31.1 million for Q4 2025. Cash decreased from $502.9M to $401.1M YoY.”

Pipeline dependency on IMpactMF interim analysis and real-world data; failure could impact growth narrative.

“In the second half of 2026, we look forward to the IMpactMF interim analysis in relapsed/refractory myelofibrosis and the first data from real-world experience trials.” · word for word

Commercial execution risk: RYTELO revenue guidance depends on successful HCP/patient targeting and market adoption in LR-MDS.

“We expect RYTELO net revenue growth to be driven by more focused HCP and patient targeting, with stronger performance in the second half of the year” · word for word

Clinical trial risk: Phase 3 IMpactMF trial in myelofibrosis is a key pipeline catalyst with inherent uncertainty.

“advancing our Phase 3 IMpactMF trial” · word for word

Workforce reduction may impact operations and morale; restructuring costs will affect near-term financials.

“RIF of ~33% of employees; $18M in charges.”

Commercial execution risk

“Our near-term prospects are wholly dependent on RYTELO. We have limited experience with the commercialization of RYTELO, and if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indication of use, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.” · word for word

Revenue concentration risk

“RYTELO is our only product approved for marketing by the FDA, and our ability to generate meaningful revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO in the U.S. for lower-risk MDS or to expand its indications of use.” · word for word

Pricing and reimbursement risk

“If we do not maintain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.” · word for word

Clinical trial risk

“We cannot be certain that we will be able to continue to develop imetelstat or advance it in clinical trials, or that we will be able to receive regulatory approval for imetelstat in any other indications in the U.S., the EU or any other region, on a timely basis or at all.” · word for word

Demand softness QoQ may indicate slower adoption or competitive pressure.

“Demand was down 3% quarter-over-quarter.” · word for word

Cash burn continues; cash decreased from $502.9M to $421.5M since year-end.

“Cash and marketable securities decreased from $502.9M to $421.5M.”